Results 21 to 30 of about 38,007 (143)

Pharmacokinetics of aminoglycoside antibiotics. Based on population pharmacokinetic data determination of the loading dose, maintenance dose and dosage interval [PDF]

open access: yesFarmacja Polska, 2021
Aminoglycosides are natural or semisynthetic antibiotics derived from actinomycetes. They bind to the bacterial ribosome, leading to inhibition of protein synthesis.
Arkadiusz Gruchlik, Marcin Kochan
doaj   +1 more source

Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences

open access: yesJEADV Clinical Practice, 2022
Background Clinical trials with dupilumab in atopic dermatitis (AD) patients showed a trend towards better effectiveness with a weekly or biweekly dosing interval, compared with extended dosing intervals.
Jill I. Olydam   +4 more
doaj   +1 more source

Flea and tick treatment satisfaction, preference, and adherence of U.S. cat owners prescribed topical fluralaner (Bravecto® Topical Solution for Cats) [PDF]

open access: yesOpen Veterinary Journal, 2021
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectoparasiticide approved in the United States for re-dosing at up to 12-week intervals for flea and tick control in cats.
Robert Lavan   +3 more
doaj   +1 more source

Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner [PDF]

open access: yesOpen Veterinary Journal, 2021
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in cats.
Robert Philip Lavan   +4 more
doaj   +1 more source

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

open access: yesTherapeutic Advances in Neurological Disorders, 2021
Background: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis.
Helmut Butzkueven   +10 more
doaj   +1 more source

An extended interval dosing method for gentamicin in neonates [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2001
Traditional gentamicin dosing every 8-24 h depending on age and weight in neonates does not provide the ideal concentration-time profile to both optimize the concentration-dependent killing by aminoglycosides and minimize toxicity. Fifty-three neonates were audited prospectively while receiving gentamicin 2.5 mg/kg every 8-24 h, aiming for peak ...
Stickland, M. D.   +5 more
openaire   +5 more sources

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? [PDF]

open access: yesNeurotherapeutics, 2020
Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab.
Clerico, Marinella   +27 more
openaire   +6 more sources

A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides [PDF]

open access: yesClinical Infectious Diseases, 1997
We conducted a meta-analysis of 22 randomized, controlled trials in which extended-interval dosing of aminoglycosides was compared with multiple daily dosing. When we classified intermediate outcomes as successes, we found that patients receiving extended-interval dosing were at significantly reduced risk of clinical treatment failure (risk difference,
T C, Bailey   +4 more
openaire   +2 more sources

Extended interval dosing with ocrelizumab in multiple sclerosis [PDF]

open access: yesMultiple Sclerosis Journal
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS). Methods: This is a prospective, double ...
Frederik Novak   +12 more
openaire   +6 more sources

Home - About - Disclaimer - Privacy